Skip to main content
. Author manuscript; available in PMC: 2023 Jul 19.
Published in final edited form as: Cell Rep. 2022 Jul 26;40(4):111095. doi: 10.1016/j.celrep.2022.111095

Figure 7. Model of sensitivity and insensitivity of NB to MAPK pathway inhibitors.

Figure 7.

(A) We refer to type I NB as RAS/RAF MT NBs relatively sensitive to MEK inhibition and insensitive to SHP2 inhibition.

(B) We refer to type II NB as RAS/RAF WT NBs with mutant/low NF1 that are sensitive to SHP2 inhibition and relatively insensitive to MEK inhibition.

(C) We refer to type III NBs (RAS/RAF/NF1 WT). These are insensitive to SHP2 or MEK inhibitors.